Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer

Authors : Birol OCAK, Süreyya SARIHAN, Ahmet Bilgehan ŞAHİN, Bahar DAKİKİ, Burcu CANER, Kemal GÜLŞEN, Özgür TANRIVERDİ, Adem DELİGÖNÜL, Erdem ÇUBUKÇU, Türkkan EVRENSEL

Pages : 71-80

Doi:10.46310/tjim.1076459

View : 17 | Download : 12

Publication Date : 2022-04-01

Article Type : Research Paper

Abstract :Background: In non-small cell lung cancer insert ignore into journalissuearticles values(NSCLC);, immunotherapy is a treatment option in patients without targetable mutations in second and later lines. Nevertheless, there is no validated test that can predict immunotherapy response. Material and Methods: Our study aimed to investigate the effect of radiotherapy insert ignore into journalissuearticles values(RT); on survival in patients with NSCLC receiving immunotherapy after first-line chemotherapy. Twenty-five patients diagnosed with NSCLC and received immunotherapy after at least one previous chemotherapy line were included in our study. Results: The median age of the patients was 61.7 insert ignore into journalissuearticles values(26.6-81.2); years. 19 insert ignore into journalissuearticles values(76%); patients were male. 11 insert ignore into journalissuearticles values(44%); of the patients had received immunotherapy in the second-line and 14 insert ignore into journalissuearticles values(66%); in ≥3 lines. Patients had received a median of 5 cycles insert ignore into journalissuearticles values(1-27); of immunotherapy. RT to immunotherapy interval was 6.4 months insert ignore into journalissuearticles values(1.0-11.8);. Partial response was observed in 12 patients, stable disease in 8 patients, progression in 1 patient, and hyperprogression in 4 patients. Median progression-free survival insert ignore into journalissuearticles values(PFS); was 4.4 months insert ignore into journalissuearticles values(95% CI; 3.2-5.6);, and median overall survival insert ignore into journalissuearticles values(OS); was 16.4 months insert ignore into journalissuearticles values(95% CI; 5.6-27.3);. 14 insert ignore into journalissuearticles values(56%); of the patients had received RT. RT was administered to 12 patients before immunotherapy, and two patients received RT to bones during immunotherapy. The patients who received RT had statistically longer PFS insert ignore into journalissuearticles values(4.9 vs 3.9 months, p=0.012); and OS insert ignore into journalissuearticles values(18.7 vs 7.3 months, p=0.023); comparing those without RT. Conclusions: Our findings showed that RT significantly improved the survival in patients who received immunotherapy, pointing that RT may have an influential role in immunotherapy response.
Keywords : Immunotherapy, radiotherapy, efficacy, non small cell lung cancer